129 results
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
Purchasers.
Item 16F.
Change in Registrant’s Certifying Accountant.
Item 16G.
Corporate Governance.
Item 16H.
Mine Safety Disclosure.
PART III
Item 17 … .
The commencement of clinical trials can be delayed for a variety of reasons, including delays in:
demonstrating sufficient safety and efficacy to obtain
20-F/A
2023 FY
EX-4.87
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
manufacturing controls documents, safety and efficacy study documents as applicable to the Product (“Product Data”) and (ii) other technical … , safety and efficacy data, formulary submissions, pharmaco-economic data, and other such information useful or required in preparing applications
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
other things, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA … safety and efficacy data for Oxycodone ER that may be obtained from human abuse potential studies for the oral and intranasal routes of administration
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:29pm
, safety or efficacy, patent issues associated with the product, and FDA and Health Canada review times.
Dexmethylphenidate Hydrochloride … . The Advisory Committees expressed a desire to review the additional safety and efficacy data for Oxycodone ER that may be obtained from human abuse
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:23pm
, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA and Health Canada … in the product label for the intravenous route of administration. The Advisory Committees expressed a desire to review the additional safety and efficacy
6-K
EX-99.1
tz13jlrq1x0c7tam2605
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.1
su6x0anjla
21 Jul 22
Current report (foreign)
5:28pm
20-F/A
2ifb27qc1109c jwrh5
6 May 22
Annual report (foreign) (amended)
7:54pm
6-K
EX-99.1
7whfj5x2slykkb0r6
14 Apr 22
Current report (foreign)
4:46pm
6-K
EX-99.1
xh2cg2iy2um 4cke7dm
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.3
6b50x7tvipcylvkmc
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.1
cppuc 1bht
28 Feb 22
Primary Document
9:56pm
6-K
EX-99.1
35zhximp 51zc
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.3
g9z7dt
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.1
e2vpzw1pswc9r6p
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.3
drh9cco8pd9i4 d3
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.3
1ie4kave5kch9rcgq
14 Apr 21
Primary Document
7:50am